Abivax S.A.
AAVXF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.13B
Close$
$7.80
94.4% downside
Current Fair Value
94.4% downsideOvervalued by 94.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $12.13 Billion |
|---|---|
| Enterprise Value | $11.74 Billion |
| Earnings per Share | $-4.83 |
| Beta | -0.21 |
| Outstanding Shares | 79,647,974 |
Return
| Return on Equity | -133.12% |
|---|---|
| Return on Assets | -105.49% |
| Return on Invested Capital | -104.99% |
Valuation & Multiples
| P/E Ratio | -16.71 |
|---|---|
| PEG | -101.15 |
| Price to Sales | - |
| Price to Book Ratio | 34.75 |
| Enterprise Value to Revenue | 5863.27 |
| Enterprise Value to EBIT | -28.64 |
| Enterprise Value to Net Income | -25 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 21, 2026
EPS Estimate
$-0.92
Consensus analyst estimateRevenue Estimate
$796,823
Consensus analyst estimateNext Earnings Call
Expected Date
December 14, 2026
EPS Estimate
$-0.86
Consensus analyst estimateRevenue Estimate
$892,477
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Abivax
69 employees
CEO: Marc de Garidel
Based in Paris, France, ABIVAX Société Anonyme is a biopharmaceutical company dedicated to the discovery and optimization of novel drug treatments. Their research and development efforts primarily target inflammatory conditions, infectio...